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Introduction
Enteric fever is an infection caused by Salmonella enterica 
subspecies enterica serovars Typhi and Paratyphi. It remains a 
considerable global health challenge, causing an estimated 14.3 
million (12·5–16·3) infections and 136 000 deaths annually1. 
Until recently2, licensed vaccines for S. Typhi were only mod-
erately efficacious3 and could not be used in young children. 
There are currently no licensed vaccines for S. Paratyphi4. 
Both serovars are human host-specific pathogens, and animal 
models have limited utility to screen candidate vaccines in a 
biologically relevant system5.
Controlled human infection models (CHIM) of typhoid or 
paratyphoid infection could represent a solution to this prob-
lem. Such models of typhoid infection have been in exist-
ence for several decades, first established by the University of 
Maryland in 1952 and used for a series of studies until 19746. 
Six S. Typhi and Paratyphi controlled human infection model 
studies have since been conducted at the University of Oxford 
(UK) between 2011 and 2017 (Extended data, Supplementary 
Table 17). The use of these, and similar, models are projected to 
increase8. An improved understanding of the factors motivating 
individuals to volunteer for challenge studies could help to 
expand their use, to optimise the extent and detail of study 
information imparted, and to refine the consent procedures used.
Participant motivation and personal experiences are impor-
tant considerations in the design and delivery of CHIM stud-
ies. Identification and recruitment of willing volunteers for such 
studies can pose distinct challenges—in a recent study 120,000 
potential recruits were contacted to recruit 112 participants9,10. 
One study on the experiences and perceptions of partici-
pants in a malaria challenge study in Kenya focussed on ethical 
considerations appropriate to a malaria endemic setting11. 
There is otherwise a paucity of research on factors motivating 
participants to enrol in human challenge studies. In particular, it 
is unclear as to whether financial considerations are the main 
driver and whether level of education should be an impor-
tant inclusion criterion when recruiting volunteers to challenge 
studies11. An improved understanding of participant experience 
could help optimise the design and conduct of future challenge 
studies. We conducted a quantitative survey of the participants 
in enteric fever challenge studies, with the aim of exploring 
the motivations, attitudes and factors influencing participation 
in human challenge research.
Methods
The survey
A survey on participant motivation and experience was included 
in every enteric fever CHIM study conducted at the Centre for 
Clinical Vaccinology and Tropical Medicine in Oxford. The 
survey population consisted of healthy adults, aged 18–65 years, 
enrolled in one of the six studies performed during the time 
period chosen (Extended data, Supplementary Table 17).
Data collected from nested surveys in six separate trials were 
combined to obtain a more representative overview of motivating 
factors and attitudes towards participation. All parent trials were 
conducted at a single site and used comparable inclusion and 
exclusion criteria10,12–14. The different trial sizes resulted in a vari-
able contribution of survey participants; however, the identical 
eligibility criteria and catchment area ensured comparable study 
populations. Non-probability sampling of the trial participants 
occurred as survey participation relied on voluntary response.
Participants were provided with a 48-question semi-structured 
survey at follow-up appointments pre-specified in the trial 
protocol (either day 28 or day 60 after challenge). The time-
point was chosen opportunistically to capture experiences 
immediately after completing the challenge period. The protocol 
specified study investigators should invite participants to com-
plete the survey on one occasion. Participants provided written 
consent at enrolment and additional verbal consent prior to com-
pletion. The questionnaire was self-administered and returned 
anonymously.
The bespoke questionnaire (available as Extended data7) was 
developed in-house, based on a published study exploring 
the attitudes and experiences of healthy volunteers in phase 
one trials15. Demographic information on occupational sta-
tus, income level, education and social support were collected 
using a multiple-choice format with pre-defined categories. 
Demographic characteristics of the participants in each study 
are described elsewhere10,12–15. No identifying information was 
included on the questionnaire to ensure anonymity. Where 
appropriate, questions on motivation and attitudes utilised the 
Likert scale16 a four- or five-point scale with pre-defined 
responses, allowing the respondent to express how much they 
agree or disagree with a given statement.
The survey tool was electronic in two trials (with the option 
of a paper version if preferred) and exclusively paper in four 
studies. Emails prompting participants to fill out the elec-
tronic survey was sent out in two studies. Participants could 
choose to complete the questionnaire in the waiting room 
after a study visit or to return it at a later date. Questionnaires 
were returned in a blank, sealed envelope and deposited in 
a collection box at the reception. 
The data were transcribed into an electronic spreadsheet and 
collated by non-study investigators. A descriptive data analy-
sis was performed using Microsoft Excel 16.0 and R 3.5.1 
statistical software.
The CHIM studies
The specific aims, trial design and results of the included stud-
ies are described elsewhere10,12–14,17. All studies were adver-
tised by several modalities, including poster advertising, tar-
geted mail drops and social media. The adults were required to 
initiate contact with study staff at the Oxford Vaccine Group 
(OVG), at which point they were provided with written 
information and telephone screened. Extensive pre-study 
counselling was then performed for interested individuals, con-
sisting of a structured 90-minute consultation with a study 
physician. To confirm agreement with study participation, 
individuals provided written informed consent.
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Screening for study inclusion/exclusion criteria included a 
medical history, physical examination, blood screening, electro-
cardiogram and an ultrasound examination of the gallbladder. 
Eligible candidates were assessed seven days prior to receiv-
ing the challenge agent, to re-explain the trial if required, 
re-assess eligibility and reconfirm consent.
Challenge study procedures and safety measures are detailed else-
where10,12–14. The participants were reviewed daily for 14-days 
following challenge, which involved a clinical evaluation 
plus blood and stool sampling.
Participant reimbursement
Participants were reimbursed for participation using a stand-
ardised template, including: £15 (17 EUR, 19 USD) per 
visit for travel expenses; £10 (11 EUR, 13 USD) per dona-
tion for inconvenience of blood tests; £20 (23 EUR, 25 USD) 
per visit for time required for visit; £100 (114 EUR, 127 
USD) for endoscopy (study OVG2014/01; Extended data, 
Supplementary Table 17); £150 (171EUR, 191USD) reim-
bursement per day for 10 days of potential time off work. 
The maximum reimbursement was £3275 (3729 EUR, 4164 
USD) for study 1, £3350 (3815 EUR, 4259 USD) for study 
2, £3305 (3763 EUR, 4202 USD) for study 3, £2930 (3337 
EUR, 3725 USD) for study 4, £3655 (4165 EUR, 4647 USD) 
for study 5 and £2750 (3125 EUR, 3496 USD) for study 6. 
The amount of financial reimbursement was determined fol-
lowing consultation with local Research Ethics Committees. 
The aim was to compensate adequately for the time and incon-
venience involved, including potential loss of earnings and 
travel expenses.
Ethical approval
All trials were conducted in accordance with the relevant 
clinical trial protocols, the principles of the Declaration of 
Helsinki, and the International Conference on Harmonization 
(ICH) Good Clinical Practice standards. Ethical approval for 
all six Oxford CHIM studies was provided by the South Cen-
tral, Oxfordshire Research Ethics Committee A (Extended data, 
Supplementary Table 17). The data were anonymized.
Results
Studies were conducted between November 2011 and August 
2017. Our pooled analysis included 201 individuals from six 
nested surveys which were offered to 421 individuals giving 
an overall response rate of 47.7%. The individual studies had 
different sample sizes (Table 1) and response rates varied 
from 33–86% of total participants (Figure 1). One survey was 
excluded due to insufficient data. The denominators for each 
question are variable; not every question was answered by 
every respondent. There was <5% missing data per question. 
Individual participant responses are available as Underlying 
data18; summary statistics are available as Extended data7.
Demographics: all participants
The median age of participants from all studies was 27 
years (interquartile range 23–38), Figure 1A. In the cohort, 
113 of 198 participants (57.0%) were educated to bachelor’s 
level or higher, 122 (61.6%) of the 198 respondents were 
in employment or self-employed, 60 (30.3%) were stu-
dents and 9 (4.6%) were unemployed (Figure 1D). The modal 
annual income was <£10,000, reported by 56 (28.6%) of the 
196 participants (Figure 1F). Overall, 91 (46.2%) of the 197 
respondents felt that they could receive social support from a 
partner they lived with. A breakdown of these data by study 
is provided in Table 2. To encourage candour in responses 
and for the purposes of anonymisation, patient specific details 
were de-linked from individual questionnaires. Consequently, 
we are unable to analyse the demographics of participants 
who responded to the questionnaire as compared with those 
who did not.
Descriptive analysis
Knowledge of typhoid or paratyphoid infection prior to 
participation was low, with 177 (88.5%) of 200 respond-
ents reporting “little” or “no” knowledge of enteric fever. In 
total, 84 (42.0%) of 200 respondents reported that they knew 
“little” of clinical trials before participating and 14 (7.0%) 
had “never” heard about clinical trials before. Specifically, 
117 (58.8%) of the 199 participants reported little or no 
prior knowledge of human challenge studies.
In response to the statement that “financial reimbursement 
was a motivation for joining this study”, 166 (82.6%) of 201 
respondents “agreed” or “strongly agreed” (Figure 2A). If 
there had been no financial reimbursement offered, 129/197 
(65.5%) participants stated that they would not have taken part 
in the study. With reference to reimbursement levels, 129/198 
(65.2%) participants felt that the amount received was “fair” 
amount and 65/198 (32.8%) thought that the compensation was 
“generous”. The modal bracket of minimum financial reim-
bursement that participants would accept for taking part in a 
similar study in the future was “£2,000 – £2,500”, as indicated by 
46 (23.3%) of 198 respondents.
The opportunity to participate in a clinical trial was a motivat-
ing factor for many of the respondents, with 139 (69.2%) agree-
ing or strongly agreeing with this statement (Figure 2A). In 
response to the statement that wanting to “contribute to the 
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Figure 1. Demographic Characteristics of Participants. (A) Age at Time of Challenge for all enteric fever CHIM studies, divided by 
sex (B) Questionnaire response rate per study. Dotted line represents median response rate; (C) Enrolment: Exclusion ratio per study; 
(D) Occupational status at time of challenge; (E) Educational attainment; (F) Annual income.
progress of medicine was a motivating factor”, 170 (84.6%) 
“agreed” or “strongly agreed”. The motivation to join the study 
to “learn more about one’s own health” ranked lowest low, 
with 109 (54.2%) participants agreeing or strongly agreeing 
with this statement.
The majority of those surveyed (166/199; 83.4%), were “very 
satisfied” with the information provided before the study. 
All 199 respondents felt that the information in the study 
booklet was not difficult to understand; 52 (22.9%) reported 
that it was “easy” to understand and 147 (77.1%) felt that 
it was “very easy” to understand. Similarly, they answered that 
the verbal information given during the screening visit was 
not difficult to understand, with 177 (88.9%) feeling that it 
was “very easy” to understand.
Less than 5.0% of the participants were “very concerned” about 
possible study-related risks such as hospitalisation or compli-
cations from enteric fever infection (Figure 2B). Before decid-
ing to take part in the study, 46 (23.2%) of 198 participants 
thought that the study was “not risky at all” and 91 (46.0%) 
perceived that it held a “slight risk”. Overall, 137 (68.5%) of 
200 respondents asked someone else’s opinion before enrolling 
in the trial. Many participants approached more than one person; 
62 (31.0%) of the study population conferred with a relative, 
64 (32.0%) with their partner and 69 (34.5%) with a friend. 
Only 13 (6.5%) asked their GP for advice before the study. 
When asked about the reaction of other people during 
discussions about participation in the study, 64 (33.3%) of 
192 respondents indicated that, “some said that it was a good 
idea, and some said it was a bad idea”. A further third, 64 
(33.3%), indicated that “almost all of them said that taking part 
in the study was a bad idea”. The majority, 139 (70.6%), of 197 
respondents reported that most people advised them against 
joining the study because of the potential risk to the participant 
and 53 (27.0%) reported that the deterrent was the perceived 
risk of transmitting the infection to others (Figure 2B).
For 110 (55.6%) of 198 survey respondents, the challenge study 
was their first participation in a clinical trial. Approximately 
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    Secondary 4 (13.8) 7 (24.1) 4 (13.3) 9 (17.3) 5 (14.3) 2 (9.1) 31 (15.7)
    A Level 4 (13.8) 8 (37.9) 7 (23.3) 9 (17.3) 12 (34.3) 10 (45.5) 53 (27.0)
    Bachelor’s 14 (48.3) 11 (27.6) 10 (33.3) 21 (40.4) 13 (37.1) 3 (13.6) 69 (35.0)
    Higher Degree 7 (24.1) 3 (10.3) 9 (30.0) 13 (25.0) 5 (14.3) 7 (31.8) 44 (22.3)
Total 29 (100.0) 29 (100.0) 30 (100.0) 52 (100.0) 35 (100.0) 22 (100.0) 197(100.0)
Missing 2 1 0 1 0 0 4
Employment฀
    Student 8 (26.7) 3 (10.3) 14 (46.7) 16 (30.8) 12 (34.3) 7 (31.8) 60 (30.3)
    Employed 16 (53.3) 15 (51.7) 12 (40.0) 26 (50.0) 15 (42.9) 10 (45.5) 94 (47.5)
    Self-employed 3 (10.0) 8 (27.6) 1 (3.3) 7 (13.5) 6 (17.1) 3 (13.6) 28 (14.1)
    Unemployed 2 (6.7) 1 (3.5) 3 (10.0) 1 (1.9) 0 (0.0) 2 (9.1) 9 (4.6)
    Other 1 (3.3) 2 (6.9) 0 (0.0)  2 (3.9) 2 (5.7) 0 (0.0) 7 (3.5)
Total 30 (100.0) 29 (100.0) 30 (100.0) 52 (100.0) 35 (100.0) 22 (100.0) 198 (100.0)
Missing 1 1 0 1 0 0 3
Annual Income
    < £10,000 8 (26.7) 5 (17.2) 13 (43.3) 13 (25.5) 11 (32.4) 6 (27.3) 56 (28.6)
    £10,000 – £20,000 7 (23.3) 8 (27.6) 7 (23.3) 14 (27.5) 13 (38.2) 3 (13.6) 52 (26.5)
    £20,000 – £30,000 9 (30.0) 9 (31.0) 6 (20.0) 13 (25.5) 5 (14.7) 8 (36.4) 50 (25.5)
    £30,000 – £40,000 5 (16.7) 4 (13.8) 1 (3.3) 9 (17.7) 4 (11.8) 2 (9.1) 25 (12.8)
    > £40,000 1 (3.3) 3 (10.3) 3 (10.0) 2 (3.9) 1 (2.9) 3 (13.6) 13 (6.6)
Total 30 (100.0) 29 (100.0) 30 (100.0) 51 (100.0) 34 (100.0) 22 (100.0) 196 (100.0)
Missing 1 1 0 2 1 0 5
Social Support
    No-one 6 (20.0) 3 (10.3) 3 (10.0) 14 (26.9) 11 (32.4) 2 (9.1) 39 (19.8)
    Friends 6 (20.0) 4 (13.8) 10 (33.3) 12 (23.1) 7 (20.6) 3 (13.6) 42 (21.3)
    Partner 12 (40.0) 19 (65.5) 13 (43.3) 20 (38.5) 13 (38.2) 14 (63.6) 91 (46.2)
    Relative 1 (3.3) 3 (10.3) 6 (20.0) 9 (17.3) 3 (8.8) 4 (18.2) 26 (13.2)
   Acquaintance 5 (16.7) 2 (6.9) 2 (6.7) 1 (1.9) 0 (0.0) 1 (4.6) 11 (5.6)
    Other 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.5)
Total 30 (100.0) 29 (100.0) 30 (100.0) 52 (100.0) 34 (100.0) 22 (100.0) 197 (100.0)
Missing 1 1 0 1 1 0 4
half, 105/198 (53.0%), of the survey respondents reported 
developing either typhoid or paratyphoid infection during the 
challenge studies. Overall, 73 (69.5%) of these felt that the 
experience of enteric fever infection was “as expected as or 
better than expected” (Figure 2C) and 32 (30.5%) felt that 
it was somewhat “worse” than they expected. Of the 196 
participants that responded to questions about time off work, 
103 (52.6%) did not take any days off work during the study; 
52 (26.5%) took <2 days off work, 25 (12.8%) took 3–4 days 
and 16 (8.2%) needed >4 days of sick leave. 
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When asked to indicate the level of satisfaction they had 
with the care they received from the staff during the study, 
184 (94.2%) of the 199 respondents were “very satisfied”. A 
high proportion of respondents would take part in the study 
again, with 177 (90.3%) of 196 respondents indicating “yes”. 
To the question, “would you recommend participation in a 
challenge study to a friend or relative?” the modal response 
was “probably” from 155 (79.1%) of 196 respondents.
Discussion
This survey represents the first comprehensive analysis of par-
ticipant motivations for, and experiences of, participating in 
typhoid and paratyphoid CHIM studies. These data suggest 
that participants were motivated by a range of factors, with a 
desire to contribute to the progress of medicine was the most 
frequently cited motivator for participation. The offer of finan-
cial reimbursement was the most important additional driver for 
attracting participation to this type of research and, for many, 
was a necessary pre-requisite. Generally, participants perceived 
the risks of participation to be low, in contrast to their close 
household contacts and relatives. These data provide valu-
able information to investigators conducting challenge 
studies in high-income, non-disease-endemic settings.
Participants in the survey reported that the chance to contribute 
to science and curiosity about clinical trials were strong moti-
vating factors, combined with financial reimbursement. Similar 
to other healthy-volunteer studies19, most participants reported 
that they would not have taken part without reimbursement. 
An unexpected finding was that a substantial proportion of 
our survey participants (35%) would have taken part with 
just their basic expenses met. Some studies have suggested that 
volunteers in early-phase trials may have an objective financial 
need but they leverage their emotions as the rationale for 
participation20, whereas other studies have suggested that par-
ticipation is seldom altruistic and primarily driven by financial 
compensation21. In keeping with this study, one system-
atic review suggested that motivation to participate in clinical 
trials is driven by a combination of financial and humanitarian 
reasons22. These data are indicating that the decision to par-
ticipate in challenge studies was likely to be multifactorial 
and one can speculate that these are influenced by a variety of 
economic and socio-demographic factors not captured by this 
survey.
These data show that most of the respondents perceived the 
risk of participating in a challenge study to be low. A recent 
survey of the motivations of 1,200 healthy volunteers in phase I 
clinical trials, conducted in three high-income countries, 
found that most participants rated the consideration of risks 
as even more important to their enrolment decisions than the 
amount of money offered23. Ultimately, the participants 
enrolled anyway, having assessed the risk themselves; a phe-
nomenon that has been previously described in a study explor-
ing the personality characteristics of healthy volunteers15. It is 
notable that most of the responders who were diagnosed 
with enteric fever, an adverse experience, still felt positive 
about their participation in the study.
Figure 2. Survey responses. (A) Distribution of strength of agreement with statements on motivation for participants joining the study. 
N =201. (B) Level of concern in response to statements regarding potential risks in participation. (C) Participants comparing experience 
of (para)typhoid infection with prior expectation.
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Remarkably, a third of the survey participants revealed that 
their contacts thought that enrolling in a challenge study was 
a bad idea. A significant proportion of contacts who advised 
the participants against study enrolment were concerned 
about the potential for them to transmit typhoid to others. This 
raises the question as to whether close-contacts should be con-
sented for third party risk, and whether this would justify 
forfeiting a participants’ right to anonymity.
There was no strong evidence of financial inducement detected 
in this study. Most participants were in paid employment, with 
only 4.6% describing themselves as unemployed. The modal 
income was less than £10,000 a year; however, a third of the 
cohort were students, comparable to 23% of Oxford’s adult 
population24, who may have relatively lower living expenses. 
In response to this potential risk, the exact remuneration for 
participation in CHIM studies were carefully considered and 
required justification as part of the ethical approval process. 
The financial reimbursement was decided based on several 
factors including travel expenses, multiple clinic visits, the 
inconvenience of each study procedure and the potential for 
lost earnings due to sickness. It has been suggested that it 
is a participant’s perception of their economic circumstances—
rather than the absolute amount reimbursed—that primarily 
influences their decision to participate in a clinical trial20. Previ-
ous studies have demonstrated an inverse correlation between 
education and financial reward as a motivator and education, 
suggesting that highly educated people may be less likely to 
need the money or less susceptible to financial inducement15. 
As these studies were set in a high-income context the sur-
vey results may not be generalizable to low-income countries 
where (at present) ~7% of challenge studies are conducted8 
and the ethics of financial benefits may need a higher level 
of scrutiny11.
The limitations to the survey approach are acknowledged. 
The survey relied on voluntary participation and yielded vary-
ing response rates from the six included CHIM studies. The low 
response rate from some of the studies may have introduced 
some selection bias25. Though the demographic data were simi-
lar across the CHIM studies, the study with an 86% response 
rate had a higher proportion of participants with a higher degree, 
compared to the two studies with the lowest response rates. 
It is possible that the CHIM participants with a higher 
educational attainment were more likely to respond to the 
survey than those with a lower attainment. Although we 
present the age distribution of the parent studies, we did not 
capture the age and gender of the survey respondents, which may 
have hidden disparities in attitudes; a previous study on the 
motivations of healthy volunteers observed that the younger 
participants were motivated by financial gain, whereas the 
older participants were attracted by a free medical screening 
or contributing to the benefit of others19. Difference in 
responses based on the demographic strata would provide 
more in-depth interpretation and understanding of the data and 
will be included in future studies.
These data may only be applicable to challenge models asso-
ciated with the development of clinical disease, rather than 
model designed to assess carriage or other surrogate meas-
ures of infection26. Self-reported data, which can introduce 
a systematic error in the measurement of opinions, as posi-
tive responses tend to be favoured in surveys27. Using a self- 
administered survey may have introduced some random 
measurement error, as it was not possible to ensure that the 
questions were understood in the same way. In-depth inter-
views could be applied in future studies to explore the issues 
raised in greater depth.
In conclusion, although financial compensation is a very impor-
tant factor considered by CHIM study participants, it forms 
part of a multifactorial decision-making process and does 
not negate the consideration of risk. Although there was no 
clear evidence of financial inducement to participate in the 
CHIM studies, we cannot definitively conclude that it did not 
occur. These data describe a cohort with a relatively high socio-
economic status and may not be generalizable to low-resource 
settings. These findings can be used to optimize participant 
experience and are useful as the design of challenge studies 
continues to evolve. Further studies are needed to determine 
whether education and employment are causally associated 
with financial inducement, particularly if CHIM studies are to 
increase in low and middle-income countries.
Data availability
Underlying data
Figshare: Enteric Fever Challenge Participant Survey Data. 
https://doi.org/10.6084/m9.figshare.990142118.
This project contains the following underlying data: 
•฀฀฀฀Day_26_append (Participant questionnaire raw data 
from typhoid/paratyphoid challenge studies; TYGER, 
PATCH, VAST).
Extended data
Figshare Repository: Enteric Fever Survey Extended Data. 
https://doi.org/10.6084/m9.figshare.9902174.v17.
This project contains the following extended data: 
•฀฀฀฀Paper summary typhoid (summary statistics from survey 
data).
•฀฀฀฀Questionnairetext (Questionnaire tool used in this study).
•฀฀฀฀Supplementary Table 1 (Description of parent 
challenge studies).
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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